• Posted 15-Dec-2020

THE UNIVERSITY OF CYPRUS MEDICAL SCHOOL PARTICIPATED WITH AN INTERVENTION TO A PUBLIC MEETING FROM EMA (EUROPEAN MEDICINES AGENCY) ON COVID-19 VACCINES

EMA (European Medicines Agency) organised a public meeting on 11 December 2020 to inform European citizens about the EU regulatory processes for the approval of COVID-19 vaccines and the Agency’s role in their development, evaluation, approval and safety monitoring.

The COVID-19 pandemic is an unprecedented global crisis, with devastating health, social and economic impact. Safe and effective vaccines for COVID-19 are urgently needed to respond to this crisis and reduce its effects. The public meeting informed citizens about EMA’s role in the pandemic and of EU regulatory procedures. It also gave the opportunity to the public and stakeholder groups to speak and share their needs, expectations and any concerns, that will be considered by EMA and the European medicines regulatory network in the decision-making process. Together with the European medicines regulatory network, EMA is supporting the development of COVID-19 vaccines and has taken steps to speed up the evaluation processes for these vaccines. The Agency and its partners are doing so while ensuring that the same high regulatory standards for quality, safety and efficacy are being applied to COVID-19 vaccines.

The Assistant Professor of the Medical School of the University of Cyprus Nikolas Dietis participated with a dissertation to the public meeting of EMA.

It is worth mention that out of the 100+ applications received by the Organization for speeches, from the fields of academia, science, business and citizens, only 15 were accepted by the Organization, one of which was from the University of Cyprus.

The intervention of Assistant Professor Nikola Dieti, published in advance on the website of the European Medicines Agency and its the only one academic position from Greece and Cyprus.

Source: University of Cyprus (https://bit.ly/3oTB2SR)